Scleroderma (Systemic Sclerosis): Early Signs, Organ Complications, and Management
What Is Scleroderma?
Scleroderma (systemic sclerosis) is a rare autoimmune connective tissue disease characterized by fibrosis, vascular dysfunction, and autoimmunity. It exists on a spectrum from limited cutaneous (lcSSc) to diffuse cutaneous (dcSSc) forms.
Early Symptoms (Often Present for Years Before Diagnosis)
- Raynaud's phenomenon: Triphasic color changes (white → blue → red) in fingers/toes triggered by cold/stress. Present in >95% of patients; often precedes other symptoms by years.
- Puffy fingers / hand swelling: Non‑pitting edema, worse in morning.
- Skin thickening: Starts distally (fingers, face), may spread proximally. Skin feels tight, shiny, hides wrinkles.
- Gastrointestinal: Reflux (GERD), dysphagia, bloating, constipation/diarrhea (dysmotility).
- Musculoskeletal: Arthralgias, myalgias, contractures (flexion).
- Fatigue, weight loss, low‑grade fever.
- Respiratory: Exertional dyspnea, dry cough (early ILD).
- Digital ulcers/pitting scars: Ischemic fingertips.
Advanced / Late Complications (Organ‑Based)
| Organ System | Complications |
|---|---|
| Lungs | Interstitial lung disease (ILD) — fibrosis, honeycombing; Pulmonary arterial hypertension (PAH) — leading cause of death |
| Heart | Myocardial fibrosis → diastolic dysfunction, heart failure, arrhythmias, pericarditis |
| Kidneys | Scleroderma renal crisis (SRC): malignant hypertension, acute kidney injury, microangiopathic hemolysis (associated with anti‑RNA pol III, high‑dose steroids) |
| GI | Severe dysmotility: gastroparesis, pseudo‑obstruction, bacterial overgrowth, malabsorption, fecal incontinence |
| Vascular | Severe digital ischemia → gangrene, amputation; telangiectasias |
| Other | Calcinosis cutis, sicca syndrome (overlap Sjögren's), increased malignancy risk (lung, liver) |
Key Autoantibodies (Prognostic)
- Anti‑centromere: Limited cutaneous; lower ILD risk, higher PAH risk.
- Anti‑Scl‑70 (topoisomerase I): Diffuse cutaneous; high ILD risk.
- Anti‑RNA polymerase III: Diffuse; high SRC risk, rapid skin progression.
- Anti‑U3 RNP (fibrillarin): Diffuse; PAH, cardiac, GI involvement.
Management Principles
- Multidisciplinary care (rheumatology, pulmonology, cardiology, nephrology, GI, dermatology).
- Raynaud's: CCBs (nifedipine), PDE‑5 inhibitors, prostanoids (IV iloprost).
- ILD: Mycophenolate, cyclophosphamide, nintedanib, tocilizumab.
- PAH: ERA, PDE‑5i, prostacyclin pathway agents.
- SRC: ACE inhibitors (captopril) — lifesaving if started early.
- Skin: Immunosuppressants (MMF, methotrexate) for early dcSSc.
Multiple Sclerosis - Related Articles
- Understanding the Link Between Multiple Sclerosis and Neuropathic Pain
- Understanding Multiple Sclerosis: Early Symptoms & Onset
- Choosing the Right Multiple Sclerosis Treatment for Your Lifestyle
- What’s the Best Climate for You If You Have Multiple Sclerosis?
- Hyperbaric Oxygen Therapy for Multiple Sclerosis: A Promising Treatment
- Multiple Sclerosis Treatments: Medications & Management
- Understanding Multiple Sclerosis (MS) Attacks: Symptoms & What They Mean
